Drugs / NBL-012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05259189 | Jul 2021 → May 2022 | — | NovaRock Biotherapeutics, Ltd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2021-04-23 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - NBL-012 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
| 2021-01-08 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - NBL-012 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗
The board of directors (the “ Board”) of CSPC Pharmaceutical Group Limited (the “ Company ,” together with its subsidiaries, the “ Group”) is pleased to announce that NBL-012, a fully human antibody drug independently discovered and developed by NovaRock Biotherapeutics Limited, a subsidiary of the Company, has obtained approval of its Investigational New Drug Application (IND) from the U.S. Food and Drug Administration (FDA). |
| 2021-01-06 | NovaRock Biotherapeutics, Ltd | Regulatory NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-012 to Treat Inflammatory Diseases novarockbio.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-10-20 | NovaRock Biotherapeutics, Ltd | NovaRock Biotherapeutics Announces Exclusive License Agreement with CSPC to Develop and Commercialize NBL-012 in Select International Territories novarockbio.com ↗ |
| 2021-04-23 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - NBL-012 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
| 2021-01-08 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - NBL-012 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
| 2021-01-06 | NovaRock Biotherapeutics, Ltd | NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-012 to Treat Inflammatory Diseases novarockbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBL-012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05259189 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT05259189 ↗ |